MOAC204

Information about MOAC204

Published on October 17, 2007

Author: Jolene

Source: authorstream.com

Content

Opioid Substitution Therapy (OST) with Buprenorphine in Ukraine – Way to Prevent HIV/AIDS among IDUs:  Opioid Substitution Therapy (OST) with Buprenorphine in Ukraine – Way to Prevent HIV/AIDS among IDUs Sergii Dvoriak MD, PhD Ukrainian Institute on Public Health Policy 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention 23 July, 2007 Sydney, Australia Acknowedgement :  Acknowedgement Dr. O.Lebega - The AIDS Alliance in Ukraine O.Morozova, MA - The AIDS Alliance in Ukraine Dr. A.Viyevskiy – Kyiv City Narcology Hospital Dr. O.Yurchenko – Kyiv City AIDS Center Dr. L.Vlasenko – NGO ‘Virtus’, Dnipropetrovsk Dr. M.Skorokhodov – Donetsk Narcology Dispensary Dr. A.Mandebura – Crimea Republican Narcology Dispensary Dr. I.Blizhevskaya - Kherson Narcology Dispensary Dr. I.Podolyan - Odessa Narcology Dispensary Dr. K.Dumchev – Vinnitsa Narcology Dispensary Dr. V.Shtengelov – Ukrainian Institute on Public Health Policy Dr. I.Grishayeva – The WHO, Ukraine Dr. A.Uchtnengagen – Zurich University, Switzerland Український інститут досліджень політики щодо громадського здоров’я Ukrainian Institute on Public Health Policy Drug statistics in Ukraine, 1990-2006:  Drug statistics in Ukraine, 1990-2006 No IDU size estimations were held in 1990; Number of individuals officially registered with drug-related disorders was 123’400 in 2006; Estimated number of IDUs in Ukraine (2005-2006) is 325’000 – 425’000 Український інститут досліджень політики щодо громадського здоров’я Ukrainian Institute on Public Health Policy Prevalence of IDUs in Ukraine (MoH data):  Prevalence of IDUs in Ukraine (MoH data) HIV transmission in Ukraine:  HIV transmission in Ukraine Injection of drugs From mother to child Sexual Undetermined Data of the Ukrainian AIDS Center Український інститут досліджень політики щодо громадського здоров’я Ukrainian Institute on Public Health Policy *Note: Practices of HIV testing among IDUs, people with STDs, pregnant women and blood donors had been changing in 1996-2003. Relationship between IDU and HIV:  Relationship between IDU and HIV Український інститут досліджень політики щодо громадського здоров’я Ukrainian Institute on Public Health Policy Political context:  Political context Joint Mission of WHO/UNAIDS/UNODC on SMT in Ukraine (November, 2004):  Joint Mission of WHO/UNAIDS/UNODC on SMT in Ukraine (November, 2004) ~ 30-40% of IDUs depended from opiates should have access to SMT for get influence on both epidemics – drug use and HIV. For Ukraine, where estimated number of IDUs is 325 – 425 thousands, the need in SMT is between 60 - 200 thousands courses UNDP Pilot Project. SMT with Buprenorphine (Addnok) 2004-2005:  UNDP Pilot Project. SMT with Buprenorphine (Addnok) 2004-2005 Kyiv – 57 clients (2 fem.) Kherson – 30 clients (1 fem.) CRITERIA: Opioid dependence (ICD-10). Two or more previous unsuccessful treatment attempts (drug-free) 18 or older Readiness for the program Український інститут досліджень політики щодо громадського здоров’я Ukrainian Institute on Public Health Policy WHO-multi-site prospective study Evaluating the Efficacy of ST in Opioid Dependence and HIV/AIDS:  WHO-multi-site prospective study Evaluating the Efficacy of ST in Opioid Dependence and HIV/AIDS Overview of the Study :  Overview of the Study This was a prospective observational study with assessments at baseline, and 3- and 6- month follow-ups All assessments are related to the period of one month prior to interview The main aims of outcome evaluation were to explore changes in the following domains: Health Status and well being of individuals in substitution treatment, Community/ Social benefits, And also Programme performance General Protocol of the Study (2003):  General Protocol of the Study (2003) Dr. Vladimir Poznyak, Management of Substance Abuse, Department of Mental Health and Substance Abuse, WHO, Geneva Professor Ambros Uchtenhagen, Research Institute of Mental Health and Addiction, Zurich, Switzerland Professor Robert Ali, WHO Collaborating Centre for the Treatment of Drug and Alcohol problems, University of Adelaide (Australia) Slide13:  Data collection Sites/ Clinics involved in the study: Regional Narcology Dispensary of Kherson Region; Kiev City Narcology Hospital State data collection time frame: April 2004 – December 2004 December 2004- May 2005 Demographics, Drug Use & Treatment History:  Demographics, Drug Use & Treatment History Demographics at treatment entry:  Demographics at treatment entry Drug Use Lifetime (ASI – Lite):  Drug Use Lifetime (ASI – Lite) * Most common route of administration = intravenous Changes in Well Being and Health Status and Social/Community Benefits Some data from Poland and Lithuania are demonstrated also:  Changes in Well Being and Health Status and Social/Community Benefits Some data from Poland and Lithuania are demonstrated also Drug Use last 30 days (ASI – Lite):  Drug Use last 30 days (ASI – Lite) Drug Use last 30 days (ASI – Lite):  Drug Use last 30 days (ASI – Lite) Other opioid (poppy straw) use in the last 30 days:  Other opioid (poppy straw) use in the last 30 days Amphetamine use in the last 30 days:  Amphetamine use in the last 30 days Health Status:  Health Status *Range Health Status:  Health Status Quality of life: WHOQOL-bref:  Quality of life: WHOQOL-bref Quality of life: WHOQOL-bref:  Quality of life: WHOQOL-bref Quality of Life – Physical Domain (WHOQOL-BREF):  Quality of Life – Physical Domain (WHOQOL-BREF) Quality of Life – Psychological Domain:  Quality of Life – Psychological Domain Quality of Life – Social Domain:  Quality of Life – Social Domain Blood Borne Virus Risk Behaviour BBV-Traq *:  Blood Borne Virus Risk Behaviour BBV-Traq * * Blood Born Virus Transmission Assessment Questionnaire Blood Borne Virus Risk Behavior (BBV-Traq):  Blood Borne Virus Risk Behavior (BBV-Traq) Blood Borne Virus Risk Behavior – Injecting Practices (BBV-TRAQ):  Blood Borne Virus Risk Behavior – Injecting Practices (BBV-TRAQ) Criminal and Employment Activity:  Criminal and Employment Activity * OTI= Opiate Treatment Index- section two [Max score = 16]. Community /Social benefits Self reported criminal involvement (OTI):  Community /Social benefits Self reported criminal involvement (OTI) Programme Performance :  Programme Performance * Refers to those still receiving maintenance treatment Order of MoH # 161 of April 13, 2005:  Order of MoH # 161 of April 13, 2005 To start SMT implementation for opioid addicts with co-morbiding HIV/AIDS in following treatment organizations:… To use for this purpose buprenorphine (Addnok) which will be provided as humanitarian aid by International Charity Organization International HIV/AIDS Alliance in Ukraine / GFATM To monitor the treatment and find best models for spreading this method to all regions of Ukraine ‘The HIV/AIDS Alliance in Ukraine’ (GF-Funding) Project /2005-06/:  ‘The HIV/AIDS Alliance in Ukraine’ (GF-Funding) Project /2005-06/ Pilot Sites: Kyiv – 2 sites; Donetsk, Dnipropetrovsk, Odesa, Simpheropol, Mykolayiv, Vinnitsa, Poltava, Kherson Start of BMT – October 2005 Purpose: to broad access to ARV for HIV+ IDUs Total number of patients > 200 persons Development of SMT Programs in Ukraine, 2003 - 2007 yy.:  Development of SMT Programs in Ukraine, 2003 - 2007 yy. Український інститут досліджень політики щодо громадського здоров’я Ukrainian Institute on Public Health Policy Slide38:  Substitution maintenance therapy with ADDNOK medication in Kyiv on the basis of KCNCH “Sociotherapy” (Adherence to SMT program) National Project “Overcoming HIV/AIDS Epidemic in Ukraine“ financing GFATM – The HIV/AIDS Alliance in Ukraine:  National Project “Overcoming HIV/AIDS Epidemic in Ukraine“ financing GFATM – The HIV/AIDS Alliance in Ukraine Український інститут досліджень політики щодо громадського здоров’я Ukrainian Institute on Public Health Policy Monitoring and Evaluation of the pilot phase :  Monitoring and Evaluation of the pilot phase HIV+ and HIV- IDUs N – 200 clients in 6 sites sites Instruments: 1. For monitoring: Eligibility checklist, Patient recruitment table, Staffing table /SASQ (The Staff attitude and satisfaction questionnaire);  Focus groups   2. For evaluation: ASI-5 - Addiction Severity Index, 5 th edition (computerized version), BBV-TRAQ questionnaire (Blood borne virus transmission risk assessment questionnaire) (With baseline and 6 month follow-up data)                      Demographics:  Demographics Drug use - Lifetime (ASI – Lite):  Drug use - Lifetime (ASI – Lite) Drug use – Previous 30 days (ASI – Lite):  Drug use – Previous 30 days (ASI – Lite) * Preliminary data Drug use – Previous 30 days (ASI – Lite):  Drug use – Previous 30 days (ASI – Lite) Addiction severity index - 5:  Addiction severity index - 5 * Preliminary data Addiction severity index - 5:  Addiction severity index - 5 Blood Borne Virus Risk Behavior (BBV-Traq):  Blood Borne Virus Risk Behavior (BBV-Traq) * Preliminary data Blood Borne Virus Risk Behavior (BBV-Traq):  Blood Borne Virus Risk Behavior (BBV-Traq) Buprenorphine in tablets:  Buprenorphine in tablets 2004y - 36 000tbls = ~ $50 000 2005y - 96 000tbls = ~$125 000 2006y - 432 000tbls =~$475 000 Cost of Buprenorphine (Addnok):  Cost of Buprenorphine (Addnok) Український інститут досліджень політики щодо громадського здоров’я Ukrainian Institute on Public Health Policy Total expenditure on SMT development in Ukraine (per patient data):  Total expenditure on SMT development in Ukraine (per patient data) 197 patients at the end of January 2006 (project duration to date - 4 months) Substance cost – $42 000. Cost of infrastructure development projects – $266 000 Total expenditures – $308 000 Total expends per patient a month – $390. Український інститут досліджень політики щодо громадського здоров’я Ukrainian Institute on Public Health Policy Conclusions:  Conclusions Buprenorphine (Addnok) is effective for SMT: retention in Tx; reduction of opioids use; health status & quality of life improvement; reduction of risky behavior; decrease of criminal involvement. In phase of stabilization an effective dose of buprenorphine is ~ 8-10 mg/day. Ukrainian data are similar to Poland, Lithuania etc Political context is still ambivalent and not supportive. Public health decision-makers still are not active in terms of development of SMT in Ukraine and influencing HIV-epidemic. The country needs a new strategy and practice regarding SMT to promptly respond on the epidemic challenges. Firstly to broad access to SMT providing methadone ST. Slide53:  Thank you for your attention!

Related presentations


Other presentations created by Jolene

Smart Dust and Micro Robots
07. 01. 2008
0 views

Smart Dust and Micro Robots

2509 9h20 kessler usoinseguro
02. 05. 2008
0 views

2509 9h20 kessler usoinseguro

whats driving emerging markets
27. 09. 2007
0 views

whats driving emerging markets

Barrie Peter Pan Text Only
12. 10. 2007
0 views

Barrie Peter Pan Text Only

rutherford winterjohnson
13. 10. 2007
0 views

rutherford winterjohnson

chap3 2
16. 10. 2007
0 views

chap3 2

IntroDNACloningDNARep
16. 10. 2007
0 views

IntroDNACloningDNARep

nile hydrology
23. 10. 2007
0 views

nile hydrology

12 HACCPJuiceSeafood French
24. 10. 2007
0 views

12 HACCPJuiceSeafood French

politiques Sant Boi Pere Dorca
24. 10. 2007
0 views

politiques Sant Boi Pere Dorca

thomson
15. 10. 2007
0 views

thomson

climate change and poverty
29. 11. 2007
0 views

climate change and poverty

botnet underground economics
04. 12. 2007
0 views

botnet underground economics

Macroevolution
12. 10. 2007
0 views

Macroevolution

Roman Religion powerpoint
29. 10. 2007
0 views

Roman Religion powerpoint

2268Atakan
31. 10. 2007
0 views

2268Atakan

Banned Books
31. 10. 2007
0 views

Banned Books

Bob
01. 11. 2007
0 views

Bob

Week 3 DW Design Kimball
07. 11. 2007
0 views

Week 3 DW Design Kimball

STILLEHAVSKRIGEN3
13. 11. 2007
0 views

STILLEHAVSKRIGEN3

enhancing osh standards
14. 11. 2007
0 views

enhancing osh standards

ELISA 2004
12. 10. 2007
0 views

ELISA 2004

Climate McBean f
21. 10. 2007
0 views

Climate McBean f

PP 08 Conditioning
16. 11. 2007
0 views

PP 08 Conditioning

Ontologies in Bioinformatics
20. 11. 2007
0 views

Ontologies in Bioinformatics

laminas centroamÃrica
22. 10. 2007
0 views

laminas centroamÃrica

1World War II
23. 12. 2007
0 views

1World War II

NOAA Fisheries NMFS
28. 12. 2007
0 views

NOAA Fisheries NMFS

ClassDay4
31. 12. 2007
0 views

ClassDay4

ENGR310 1 07
03. 01. 2008
0 views

ENGR310 1 07

PAN Villarreal
22. 10. 2007
0 views

PAN Villarreal

gpr
05. 01. 2008
0 views

gpr

hansen
29. 10. 2007
0 views

hansen

3 El Hattab Ahamed
25. 10. 2007
0 views

3 El Hattab Ahamed

marrocos2
24. 10. 2007
0 views

marrocos2

NWS Partnering
05. 10. 2007
0 views

NWS Partnering

Lyster
16. 10. 2007
0 views

Lyster

webcast1
29. 10. 2007
0 views

webcast1

Chicago
15. 10. 2007
0 views

Chicago

Faridah Noor Indian Dance New
23. 11. 2007
0 views

Faridah Noor Indian Dance New

xmm UG 051606
28. 11. 2007
0 views

xmm UG 051606

ISOM7
15. 10. 2007
0 views

ISOM7

Thermocouple
16. 02. 2008
0 views

Thermocouple

Gubler
21. 10. 2007
0 views

Gubler

test5
30. 10. 2007
0 views

test5

pit 2
26. 02. 2008
0 views

pit 2

m6 Eyler
28. 02. 2008
0 views

m6 Eyler

PSCM
07. 03. 2008
0 views

PSCM

pfl powerpoint may06
10. 03. 2008
0 views

pfl powerpoint may06

Prasa2001
13. 03. 2008
0 views

Prasa2001

PresentationANALYSTE SSNI2006
24. 10. 2007
0 views

PresentationANALYSTE SSNI2006

Perine I2 22april04
16. 03. 2008
0 views

Perine I2 22april04

Panel B Igor Hansen
20. 03. 2008
0 views

Panel B Igor Hansen

kapil kaul
25. 03. 2008
0 views

kapil kaul

part1 intro
07. 10. 2007
0 views

part1 intro

ans1 ffa program
03. 04. 2008
0 views

ans1 ffa program

Jonah
07. 04. 2008
0 views

Jonah

051208 Osawa
09. 10. 2007
0 views

051208 Osawa

3arq
18. 10. 2007
0 views

3arq

Bourgeat Siam
06. 12. 2007
0 views

Bourgeat Siam

allen
08. 04. 2008
0 views

allen

Fry 2005
10. 04. 2008
0 views

Fry 2005

ValueofNonpartisan
14. 04. 2008
0 views

ValueofNonpartisan

lovelock12
16. 04. 2008
0 views

lovelock12

Pumpkin SmallSat 2006
17. 04. 2008
0 views

Pumpkin SmallSat 2006

CSAM DOJ Briefing Day2
22. 04. 2008
0 views

CSAM DOJ Briefing Day2

SOUTHEAST pp
03. 01. 2008
0 views

SOUTHEAST pp

Arbetslagsplan 04 05
02. 11. 2007
0 views

Arbetslagsplan 04 05

dentist
06. 05. 2008
0 views

dentist

critical care slides
07. 05. 2008
0 views

critical care slides

origins
08. 05. 2008
0 views

origins

mas info
08. 05. 2008
0 views

mas info

18 4
22. 10. 2007
0 views

18 4

Vulvodynia
01. 05. 2008
0 views

Vulvodynia

014 Robot Control Architectures
02. 05. 2008
0 views

014 Robot Control Architectures

3678s1 03 schechter
02. 05. 2008
0 views

3678s1 03 schechter

Dana Guerrieri
02. 05. 2008
0 views

Dana Guerrieri

Anestezja
02. 05. 2008
0 views

Anestezja

lezersp1
15. 10. 2007
0 views

lezersp1

20050928 Yasuyuki Fuchita
09. 10. 2007
0 views

20050928 Yasuyuki Fuchita

S Pathi
16. 10. 2007
0 views

S Pathi

Thompson Adjusted
30. 04. 2008
0 views

Thompson Adjusted

Poretti dscut Gdor CW8
15. 11. 2007
0 views

Poretti dscut Gdor CW8

2002 04 maintenance
19. 11. 2007
0 views

2002 04 maintenance

N1 Richard News from ELAN Paris
29. 09. 2007
0 views

N1 Richard News from ELAN Paris

cal20050303
09. 10. 2007
0 views

cal20050303

2007 FL GHC ICC Tezak Kilcollins
05. 10. 2007
0 views

2007 FL GHC ICC Tezak Kilcollins

TUD About the institution
18. 03. 2008
0 views

TUD About the institution

iPOP2007 OIF Berthold
09. 10. 2007
0 views

iPOP2007 OIF Berthold

patricia arsene
15. 10. 2007
0 views

patricia arsene

IHS 2003
27. 03. 2008
0 views

IHS 2003

MOTIVATE 1 slides
29. 10. 2007
0 views

MOTIVATE 1 slides

Alia2003
05. 10. 2007
0 views

Alia2003

RE SUNUM ppt2
23. 11. 2007
0 views

RE SUNUM ppt2

grid2000 welcome
17. 10. 2007
0 views

grid2000 welcome

Larry
07. 01. 2008
0 views

Larry

Abel
25. 10. 2007
0 views

Abel

Weitz Tracy 1 24 07
03. 01. 2008
0 views

Weitz Tracy 1 24 07

del rel
07. 11. 2007
0 views

del rel

ilc analyse
23. 10. 2007
0 views

ilc analyse

CAS 07 MDHS
02. 05. 2008
0 views

CAS 07 MDHS